Zhu Y, Olchanski N, Cohen JT, Freund KM, Faul JD, Fillit HM, Neumann PJ, Lin PJ
Injection Site Selection and Rotation Protocols All Phase 2 retatrutide dosage cohorts used subcutaneous injection as the delivery route
Mitochondrial mass assessed by NAO staining in ( a ) HCT116 cells treated with TS-targeting therapies, ( b ) non-small cell lung cancer (NSCLC) cell lines treated with pemetrexed, ( c ) HCT116 cells treated with 5FU, FOLFOX (5FU+oxaliplatin), FOLFIRI (5FU + SN38), or single agent oxaliplatin and SN38, or ( d ) HCT116 cells treated 5FU Torin or rapamycin for 72 h
Every treatment is personalized to your specific health profile and needs
And for patient populations for whom daily IV administration is a significant lifestyle disruption, oral supplementation can be a valuable addition to an individuals daily supplement regimen